Related Experiment Video
Updated: Jul 6, 2026
05:31
Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
Published on: January 26, 2024
A possible placental factor for preeclampsia: sFlt-1
1Department of Obstetrics and Gynecology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. naokoich@hsp.md.shinshu-u.ac.jp
Current Medicinal Chemistry
|March 14, 2008
Summary
Preeclampsia mechanisms remain unclear, but placental issues may cause maternal disease. Soluble fms-like tyrosine kinase-1 (sFlt1), produced by hypoxic placentas, is a key factor potentially mediating these effects.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Cardiovascular Biology
Background:
- Preeclampsia is a significant pregnancy complication with unclear underlying mechanisms.
- Growing evidence suggests a link between placental pathology and maternal systemic disease.
- Identifying factors mediating communication between the placenta and maternal circulation is crucial.
Purpose of the Study:
- To review the role of soluble fms-like tyrosine kinase-1 (sFlt1) as a potential mediator in preeclampsia.
- To explore the relationship between placental hypoxia, sFlt1 production, and preeclampsia development.
Main Methods:
- Literature review focusing on studies investigating sFlt1 in preeclampsia.
- Analysis of evidence linking placental hypoxia to sFlt1 over-expression.
- Examination of animal model data on sFlt1's effects.
Main Results:
- Hypoxic placentas, common in preeclampsia, are identified as a source of sFlt1 production.
- Animal studies demonstrate that sFlt1 over-expression can induce preeclampsia-like symptoms.
- sFlt1 is proposed as a key factor mediating placental pathology to maternal systemic effects.
Conclusions:
- Soluble fms-like tyrosine kinase-1 (sFlt1) is a strong candidate for mediating the link between placental dysfunction and maternal disease in preeclampsia.
- Further research into sFlt1's role could reveal novel therapeutic targets for preeclampsia.
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:15Transcytosis of IgG
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
01:14Fetal Circulation
Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:09Cytoskeletal Linker Proteins - Plakins
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...